Researchers Awarded $15 Million to Study Heart Valve Disease

A new four-year, $15 million research initiative funded by the American Heart Association (AHA) will support collaborative investigation into earlier detection and slowing progression of heart valve disease.

The Strategically Focused Research Network (SFRN) — focused on this prioritized topic — will be led by research teams at Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Medical Center, and the University of Pittsburgh.

Awards commenced April 1, 2026, and are intended to support joint projects across the three centers.

The AHA frames this investment against epidemiologic data in its 2026 Heart Disease and Stroke Statistics report showing that heart valve disease affects more than 80 million people worldwide and is increasing.

In the United States, the condition is reported to contribute to more than 57,000 deaths annually.

The Association emphasizes that valve disease often progresses insidiously with few early symptoms and that earlier diagnosis could expand therapeutic options, reduce complications and improve quality of life.

The AHA has identified valvular heart disease as a key focus area in its broader Heart Valve Initiative and related quality improvement work such as Target: Aortic Stenosis™.

The AHA has previously established 19 such networks across diverse topics.

Hilaire, Ph.D., FAHA, director of the Center for Integrative Valve Science and associate professor of medicine).

Elena Aikawa, M.D., Ph.D., FAHA, is named as director of the Heart Valve Translational Research Program at Brigham and Women’s.

The source lists these investigators as part of the network leadership.

• Funding mechanism: The AHA awarded four-year SFRN grants totaling $15 million to three research centers, which will undertake collaborative research projects across the network.
• Network composition: This SFRN follows the AHA’s established SFRN model in which three to six centers with complementary expertise (basic, clinical, and population/behavioral sciences) address strategic knowledge gaps in a defined cardiovascular topic.
• Lead centers and named investigators: The announcement identifies principal institutions and associated leaders: Mass General Brigham Heart and Vascular Institute (Brigham and Women’s affiliation cited); Cincinnati Children’s Hospital Medical Center (Andrea Beaton, M.D., M.S., FAHA, professor of pediatrics and pediatric cardiologist); and the University of Pittsburgh (Cynthia St.

The announcement highlights the intention to support “innovative, cutting-edge scientific exploration,” but does not provide detailed protocols or specific hypotheses for the funded projects.

• Primary thematic aim: earlier detection and delaying progression of valvular heart disease.
• Intended scientific approach: cross-center collaborative projects leveraging basic, translational and population/behavioral science expertise to identify novel diagnostic approaches and interventions that could alter disease trajectory.
• Relationship to prior AHA programs: The SFRN is presented as complementary to the AHA’s Heart Valve Initiative and quality-improvement programs aimed at aortic stenosis, with an explicit focus on extending impact earlier in disease evolution.

adults expressed confidence in the AHA as a trustworthy source of public-health information, noting the organization’s century-long role in health education, advocacy and research support.

• The AHA has a long-standing history of funding targeted research networks; the organization has invested almost $300 million in 19 SFRNs to date, each geared to a strategic research priority identified by the AHA volunteer Board of Directors.
• Broader AHA research portfolio: Since 1949 the Association reports having funded more than $6.1 billion in cardiovascular, cerebrovascular and brain health research, and it positions itself as the largest non‑profit, non‑government funder of heart and brain health research in the United States.
• Public trust and organizational mission: The announcement cites a recent Annenberg Policy Center poll in which 82% of U.S.

• Duration and timing: Awards are for four years and began April 1, 2026.
• Collaborative expectation: The three funded centers will undertake collaborative research projects, though the announcement does not enumerate specific project milestones, data sources, or endpoints.
• Reporting of concrete deliverables, publications or translational targets: The source does not specify anticipated publications, datasets, or translational products linked to the awards.

• The AHA frames earlier identification of valve disease as potentially increasing therapeutic options and preventing complications but does not provide evidence within the announcement to support specific clinical outcomes or to quantify potential benefit.
• The SFRN is intended to generate new knowledge on diagnostics and interventions earlier in disease course; precise mechanisms by which network outputs will be integrated into care pathways are not detailed in the source.

• Lack of methodological detail: The announcement describes organizational structure, high-level aims and participating investigators but does not provide study protocols, specific scientific hypotheses, sample sizes, data collection methods, or analytical plans.
• No outcome data provided: The source contains no data from the funded studies, as the projects are just beginning; therefore, no findings, efficacy metrics, or safety signals are reported.
• Scope of funding relative to needs: While the AHA reports the aggregate funding invested in SFRNs and overall research historically, the source does not discuss how the $15 million will be allocated across centers or projects, nor does it place the award in context of the total research budget for valvular disease globally.

Hilaire, Ph.D., FAHA — director of the Center for Integrative Valve Science and associate professor of medicine at the University of Pittsburgh.

Rosen, M.D., FAHA — AHA volunteer president and quoted describing the rationale and importance of early detection; also identified by institutional role at Northwell Health.

• Andrea Beaton, M.D., M.S., FAHA — professor of pediatrics at the University of Cincinnati and pediatric cardiologist at Cincinnati Children’s Hospital Medical Center.
• Elena Aikawa, M.D., Ph.D., FAHA — director of the Heart Valve Translational Research Program at Brigham and Women’s (Mass General Brigham affiliation referenced).
• Cynthia St.
• Stacey E.